EDGEWISE THERAPEUTICS INC
NASDAQ: EWTX (Edgewise Therapeutics, Inc.)
Kemas kini terakhir: semalam, 12:20AM35.32
-0.26 (-0.73%)
| Penutupan Terdahulu | 35.58 |
| Buka | 36.21 |
| Jumlah Dagangan | 984,028 |
| Purata Dagangan (3B) | 1,011,768 |
| Modal Pasaran | 3,800,185,088 |
| Harga / Buku (P/B) | 6.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| EPS Cair (TTM) | -1.55 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.06% |
| Nisbah Semasa (MRQ) | 20.99 |
| Aliran Tunai Operasi (OCF TTM) | -118.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.74 M |
| Pulangan Atas Aset (ROA TTM) | -21.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.29% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Edgewise Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.70 |
|
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 104.04% |
| Julat 52 Minggu | ||
| Median | 45.00 (27.41%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Evercore ISI Group | 27 Feb 2026 | 45.00 (27.41%) | Beli | 30.44 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DONOVAN JOANNE M. | - | 34.73 | -55,230 | -2,064,984 |
| Jumlah Keseluruhan Kuantiti Bersih | -55,230 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,064,984 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 34.73 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DONOVAN JOANNE M. | Pegawai | 05 May 2026 | Jual automatik (-) | 50,000 | 38.01 | 1,900,500 |
| DONOVAN JOANNE M. | Pegawai | 05 May 2026 | Pelaksanaan pilihan | 50,000 | - | - |
| DONOVAN JOANNE M. | Pegawai | 04 May 2026 | Jual automatik (-) | 5,230 | 31.45 | 164,484 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |